FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2322018156> ?p ?o ?g. }

• W2322018156 endingPage "e215" @default.
• W2322018156 startingPage "e215" @default.
• W2322018156 abstract "Despite documented laboratory and clinical benefits of hydroxyurea for children with sickle cell anemia (SCA), the drug's long-term safety and efficacy remains poorly defined. The HUSOFT trial and extension study examined feasibility, toxicity, and hematological efficacy of hydroxyurea in infants with SCA. This report describes HUSOFT participants who have continued hydroxyurea therapy for 15 years. With IRB approval, medical records were reviewed for clinical, laboratory, and growth parameters. Twenty-eight infants enrolled in the original 2-year HUSOFT study received open-label liquid hydroxyurea at 20 mg/kg/day; 17 completed the extension study with dose escalation to 30 mg/kg/day. Eight of these 17 (6 girls and 2 boys, all HbSS) have continued on daily hydroxyurea for at least 15 years (median age at last follow-up 17.6 years) without interruption. All hematologic indices (Hb concentration, mean corpuscular volume (MCV), fetal hemoglobin) showed sustained effect after 15 years. The median maximum tolerated dose of hydroxyurea has decreased from 30 to 26 mg/kg/day (range 19.5–31.2); neutropenia [absolute neutrophil count (ANC) < 1.0 × 109/L] prompting temporary drug discontinuation occurred a total of 10 times in 4 subjects and there was no severe neutropenia (ANC < 0.5 × 109/L). Growth rates over 15 years continued at the 50th percentile for both height and weight, and puberty occurred without delay (age range 10–14 years). There were 5.1 vaso-occlusive events (pain and acute chest syndrome)/100 patient years, 7.3 packed red blood cell transfusions/100 patient years. No malignancies, strokes, or deaths occurred. At last follow up, all subjects were at appropriate grade level (10–12 grade) with no history of repeated grades. A cohort of young teenagers with SCA who initiated treatment in infancy have had sustained and continued hematological benefits for a decade and a half. Growth and sexual development are normal and comparable to the general pediatric population. Continuous hydroxyurea therapy since infancy appears safe and efficacious in SCA." @default.
• W2322018156 created "2016-06-24" @default.
• W2322018156 creator A5006021643 @default.
• W2322018156 creator A5033166660 @default.
• W2322018156 creator A5036901969 @default.
• W2322018156 creator A5040752648 @default.
• W2322018156 creator A5068017197 @default.
• W2322018156 creator A5070268746 @default.
• W2322018156 creator A5090929774 @default.
• W2322018156 date "2014-12-01" @default.
• W2322018156 modified "2023-09-27" @default.
• W2322018156 title "From Infancy to Adolescence" @default.
• W2322018156 cites W1686382769 @default.
• W2322018156 cites W1963802507 @default.
• W2322018156 cites W1976462157 @default.
• W2322018156 cites W1994489695 @default.
• W2322018156 cites W2033040678 @default.
• W2322018156 cites W2039423483 @default.
• W2322018156 cites W2043184343 @default.
• W2322018156 cites W2049129790 @default.
• W2322018156 cites W2052482780 @default.
• W2322018156 cites W2064816037 @default.
• W2322018156 cites W2074858698 @default.
• W2322018156 cites W2077430371 @default.
• W2322018156 cites W2085507731 @default.
• W2322018156 cites W2104724413 @default.
• W2322018156 cites W2157374750 @default.
• W2322018156 cites W2170086069 @default.
• W2322018156 cites W2313541759 @default.
• W2322018156 cites W2336555111 @default.
• W2322018156 cites W4860913 @default.
• W2322018156 doi "https://doi.org/10.1097/md.0000000000000215" @default.
• W2322018156 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4603125" @default.
• W2322018156 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25526439" @default.
• W2322018156 hasPublicationYear "2014" @default.
• W2322018156 type Work @default.
• W2322018156 sameAs 2322018156 @default.
• W2322018156 citedByCount "56" @default.
• W2322018156 countsByYear W23220181562015 @default.
• W2322018156 countsByYear W23220181562016 @default.
• W2322018156 countsByYear W23220181562017 @default.
• W2322018156 countsByYear W23220181562018 @default.
• W2322018156 countsByYear W23220181562019 @default.
• W2322018156 countsByYear W23220181562020 @default.
• W2322018156 countsByYear W23220181562021 @default.
• W2322018156 countsByYear W23220181562022 @default.
• W2322018156 countsByYear W23220181562023 @default.
• W2322018156 crossrefType "journal-article" @default.
• W2322018156 hasAuthorship W2322018156A5006021643 @default.
• W2322018156 hasAuthorship W2322018156A5033166660 @default.
• W2322018156 hasAuthorship W2322018156A5036901969 @default.
• W2322018156 hasAuthorship W2322018156A5040752648 @default.
• W2322018156 hasAuthorship W2322018156A5068017197 @default.
• W2322018156 hasAuthorship W2322018156A5070268746 @default.
• W2322018156 hasAuthorship W2322018156A5090929774 @default.
• W2322018156 hasBestOaLocation W23220181561 @default.
• W2322018156 hasConcept C126322002 @default.
• W2322018156 hasConcept C172680121 @default.
• W2322018156 hasConcept C187212893 @default.
• W2322018156 hasConcept C2776317666 @default.
• W2322018156 hasConcept C2777063308 @default.
• W2322018156 hasConcept C2778248108 @default.
• W2322018156 hasConcept C2778620579 @default.
• W2322018156 hasConcept C2778715236 @default.
• W2322018156 hasConcept C2778917026 @default.
• W2322018156 hasConcept C2779134260 @default.
• W2322018156 hasConcept C2779234561 @default.
• W2322018156 hasConcept C2780976302 @default.
• W2322018156 hasConcept C2781058662 @default.
• W2322018156 hasConcept C29730261 @default.
• W2322018156 hasConcept C54355233 @default.
• W2322018156 hasConcept C71924100 @default.
• W2322018156 hasConcept C86803240 @default.
• W2322018156 hasConceptScore W2322018156C126322002 @default.
• W2322018156 hasConceptScore W2322018156C172680121 @default.
• W2322018156 hasConceptScore W2322018156C187212893 @default.
• W2322018156 hasConceptScore W2322018156C2776317666 @default.
• W2322018156 hasConceptScore W2322018156C2777063308 @default.
• W2322018156 hasConceptScore W2322018156C2778248108 @default.
• W2322018156 hasConceptScore W2322018156C2778620579 @default.
• W2322018156 hasConceptScore W2322018156C2778715236 @default.
• W2322018156 hasConceptScore W2322018156C2778917026 @default.
• W2322018156 hasConceptScore W2322018156C2779134260 @default.
• W2322018156 hasConceptScore W2322018156C2779234561 @default.
• W2322018156 hasConceptScore W2322018156C2780976302 @default.
• W2322018156 hasConceptScore W2322018156C2781058662 @default.
• W2322018156 hasConceptScore W2322018156C29730261 @default.
• W2322018156 hasConceptScore W2322018156C54355233 @default.
• W2322018156 hasConceptScore W2322018156C71924100 @default.
• W2322018156 hasConceptScore W2322018156C86803240 @default.
• W2322018156 hasIssue "28" @default.
• W2322018156 hasLocation W23220181561 @default.
• W2322018156 hasLocation W23220181562 @default.
• W2322018156 hasLocation W23220181563 @default.
• W2322018156 hasOpenAccess W2322018156 @default.
• W2322018156 hasPrimaryLocation W23220181561 @default.
• W2322018156 hasRelatedWork W1982415713 @default.
• W2322018156 hasRelatedWork W2063998893 @default.

• next